This New Pill is About to Bring Big Pharma to its Knees As Teva Obliterates IBD Trials (Shares Soar)

In the cutthroat world of pharmaceuticals, Teva and Sanofi just strutted onto the stage, flipped their lab coats, and declared, “Hold our pipettes.” The dynamic duo’s experimental drug, duvakitug (try saying that five times fast), just crushed its Phase 2b trials for inflammatory bowel disease (IBD)—aka Crohn’s disease and ulcerative colitis, the gastrointestinal menaces that make Taco Bell runs a gamble for millions.

(Source: Giphy) 

The numbers? Chef’s kiss. Ulcerative colitis patients on a high dose of duvakitug hit a 47.8% remission rate, compared to 20.45% on placebo. Over in Crohn’s-ville, 47.8% of high-dose patients achieved endoscopic responses, leaving placebo’s 13% looking like a sad participation trophy. TL;DR: Teva and Sanofi just duuuunked on the competition for a bigly win. 

(Source: Wall Street Journal) 

In short, if you haven’t been keeping up with monoclonal antibody drama, TL1A inhibitors are the hot new class of drugs for IBD (again, the disease, not to be confused with Investor Business Daily LOL). And Teva and Sanofi’s duvakitug not only hit its primary endpoints but did so with the kind of placebo-adjusted efficacy that analysts are calling “best-in-class.”

For context, Merck shelled out $10.8B last year for Prometheus Biosciences’ TL1A program, while Roche dropped $7.1B on Roivant and Pfizer’s TL1A project. But according to Evercore ISI’s Umer Raffat, Teva’s drug just one-upped both rivals, delivering superior results despite one of the highest placebo response rates in IBD trial history. Merck and Roche? Consider yourselves on notice.

(Source: Barrons) 

As a result, Teva’s stock skyrocketed 26%, hitting a high not seen since 2018, which, fun fact, was the last time anyone thought MoviePass was a good idea. Sanofi’s shares got a respectable 6.6% bump, because apparently, helping run the show doesn’t get you the same glory as being the lead actor.

Why the hype? Simple. If duvakitug can maintain this level of efficacy in Phase 3 (regulatory talks are already underway), it’s not just a drug—it’s a blockbuster. Think multi-billion-dollar sales potential, all while offering IBD patients a much-needed alternative to existing treatments like AbbVie’s Skyrizi and Rinvoq, which, by the way, aren’t even in the same TL1A league.

(Source: Giphy) 

When it comes to momentum though, Teva and Sanofi are already gearing up for Phase 3 trials, with Sanofi taking the development reins and Teva leading the charge in Europe.  If this drug makes it to market, it could seriously disrupt the IBD treatment landscape. And by “disrupt,” I mean sending their competitors in a tailspin like they just realized their stock was being bodybagged by degenerates on Reddit.  

(Source: Giphy) 

In the end, Teva and Sanofi just delivered the IBD world a one-two punch of efficacy and safety. And with their impressive share gains yesterday, if you’re not paying attention, you might want to circle back on these two. In the meantime, filter this through a brain-cell though and don’t be dumb. Place your bets accordingly, and even though Teva just gave me hope for no more “not tonight, my stomach hurts” excuses… I’m not holding my breath LOL. (If this offends you, well, then read the P.S. below… and then, go kick rocks). 

As always, stay safe and stay frosty, friends! Until next time…

P.S. On Saturday night, I took my wife out to dinner, and while it was a fantastic evening with the woman I love, the bill came in at $220 (we love premium steak here in Oklahoma). However, on the drive home, it hit me… I could’ve bought 11 frigging memberships to Stocks.News premium with that bill. ELEVEN. The crazy part? Unlike those friggin’ steaks I bought, just one Stocks.News premium membership actually has the potential to put money back into my pocket.

Now, don’t get me wrong, I wouldn’t trade that date night for anything (happy wife, happy life, right?). But seriously, think about it: That’s how ridiculously affordable Stocks.News premium is. Less than the cost of a fancy night out, and it’s packed with tools, insights, and strategies designed to help you make better financial moves.

Meaning, if you’re not in Stocks.News premium yet, what are you doing? For just $20 a month—less than what you’d shell out for a decent appetizer—it’s time to rethink where your dollars are going.  Click here to see all the details including what Stocks.News premium gets you for just $20 A MONTH…

Stocks.News holds positions in Merck & Co. as mentioned in the article.